In contrast, in some phase II (EudraCT ID 2007–000290-32) and phase III (NCT01234337) trials, the inclusion of sorafenib to capecitabin therapy did not improve survival advantage as well as imparted incidences of toxicities in HER2 − breast cancer patients [130, 131]. Here, ERBB2 is linked to breast cancer.